Mona Ashiya Biography and Net Worth

Director of Disc Medicine

Mona Ashiya is a Partner at OrbiMed Advisors LLC (“OrbiMed”) where she has been involved in a number of private and public company investments. Prior to joining OrbiMed in 2010, Mona covered the biotechnology industry as a member of J.P. Morgan’s biotechnology equity research team. Her previous experience includes positions at the Global Alliance for Tuberculosis Drug Development and the Harvard Business School. She earned a B.A. degree from the University of California at Berkeley, a Ph.D. in Cellular, Molecular, and Developmental Biology from the University of Pittsburgh, and was a post-doctoral fellow at the Dana Farber Cancer Institute.

What is Mona Ashiya's net worth?: The estimated net worth of Mona Ashiya is at least $8.21 million as of March 24th, 2025. Ashiya owns 186,541 shares of Disc Medicine stock worth more than $8,209,669 as of April 22nd. This net worth evaluation does not reflect any other assets that Ashiya may own. Learn More about Mona Ashiya's net worth.
How do I contact Mona Ashiya?: The corporate mailing address for Ashiya and other Disc Medicine executives is 297 Boston Post Road #248, Wayland MA, 01778. Disc Medicine can also be reached via phone at 617-401-4400 and via email at ir@geminitherapeutics.com. Learn More on Mona Ashiya's contact information.
Has Mona Ashiya been buying or selling shares of Disc Medicine?: Mona Ashiya has not been actively trading shares of Disc Medicine during the last ninety days. Most recently, Mona Ashiya sold 5,738 shares of the business's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $54.11, for a transaction totalling $310,483.18. Following the completion of the sale, the director now directly owns 186,541 shares of the company's stock, valued at $10,093,733.51. Learn More on Mona Ashiya's trading history.
Who are Disc Medicine's active insiders?: Disc Medicine's insider roster includes Mona Ashiya (Director), Kevin Bitterman (Director), Joanne Bryce (CFO), Jean Franchi (CFO), Rahul Khara (Insider), Brian Macdonald (Insider), John Quisel (CEO), William Savage (Insider), Pamela Stephenson (Insider), William White (Director), and Jonathan Yu (COO). Learn More on Disc Medicine's active insiders.
Are insiders buying or selling shares of Disc Medicine?: During the last year, insiders at the sold shares 21 times. They sold a total of 447,850 shares worth more than $25,068,128.17. The most recent insider tranaction occured on March, 24th when Director Mona Ashiya sold 5,738 shares worth more than $310,483.18. Insiders at Disc Medicine own 4.2% of the company. Learn More about insider trades at Disc Medicine.
Information on this page was last updated on 3/24/2025.

Mona Ashiya Insider Trading History at Disc Medicine

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/24/2025	Sell	5,738	$54.11	$310,483.18	186,541
3/21/2025	Sell	10,011	$54.00	$540,594.00	187,297
3/19/2025	Sell	39,656	$54.02	$2,142,217.12	188,981
3/12/2025	Sell	83,182	$54.45	$4,529,259.90	194,209
3/10/2025	Sell	202,146	$54.29	$10,974,506.34	208,742
12/18/2023	Sell	1,724	$59.24	$102,129.76

Mona Ashiya Buying and Selling Activity at Disc Medicine

Disc Medicine Company Overview

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $44.01

$42.93

$45.39

50 Day Range

MA: $49.27

$34.28

$56.92

2 Week Range

Now: $44.01

$25.64

$68.73

Volume

455,734 shs

Average Volume

346,992 shs

Market Capitalization

$1.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77